Business
Resverlogix Presents Two Abstracts on Analysis of the Phase 2 ASSERT Clinical Trial at The ESC Congress 2011
TSX Exchange Symbol: RVX CALGARY, Sept. 1, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\n\n\nTSX Exchange Symbol: RVX\n\n\nCALGARY, Sept. 1, 2011 /CNW/ - Resverlogix Corp. (\"Resverlogix\") (TSX:\n RVX) announced today that two abstracts on the analysis of the ASSERT\n trial were presented at the European Society of Cardiology (ESC)\n Congress 2011 in Paris, France. The abstracts were co-authored by\n Resverlogix Senior Scientists and Clinical Steering Committee members:\n S.J. Nicholls, A. Gordon, J. Johansson, C.M. Ballantyne, J.J.P.\n Kastelein, N.C.W. Wong, M. Borgman, K. Wolski, and S.E. Nissen.\n\n\nThe Phase 2 ASSERT clinical trial's lead compound RVX-208 is an orally\n active small molecule that raises Apolipoprotein A-I (ApoA-I)\n production, the key protein in high-density lipoprotein (HDL) known as\n the 'good cholesterol'.  Data gathered in the ASSERT trial showed that\n RVX-208 enhanced biomarkers of reverse cholesterol transport (RCT),\n thus reflecting robust cholesterol clearance from arterial wall plaques\n via this metabolic pathway.  This action of RVX-208 is unique and when\n added to new knowledge of the target protein bound by the compound, it\n indicates that RVX-208 is clearly different from all other drugs in the\n sphere, including cholesteryl ester transfer protein (CETP) inhibitors.\n\n\nThe current analysis of the ASSERT trial yielded new findings summarized\n in the presentation titled: \"Increasing Circulating Concentration of\n all HDL Particle Subclasses in Hyper-Responders: Insights from the\n ASSERT Study to ApoA-I Induction.\" Abstract link: http://spo.escardio.org/AbstractDetails.aspx?id=100468&eevtid=48\n\n\nDr. Jan Johansson, Resverlogix's Senior Vice President of Medical\n Affairs, highlighted the significance of this observation noting that,\n \"enhanced RCT is a highly sought after goal in drug development because\n it gives us a chance to regress atherosclerosis within the vessel\n wall.  This new data helped identify a large high-risk patient\n population with low HDL levels whereby significant benefit may be\n gained from the actions of RVX-208.\"\n\n\nThe second ESC presentation titled: \"Apolipoprotein A-I Induction\n Therapy is Associated with Reduction in Inflammatory Biomarkers:\n Potential Implications for Functionality of High-Density Lipoproteins,\"\n demonstrated the potential of RVX-208 in lowering CRP, a recognized\n biomarker of card...